65 activities found

Webcast: Meet the Experts: English-speaking Healthcare Professionals at Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies

Meet the Experts, recorded at Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies, is a panel discussion between Dr. Morton Coleman, Dr. Tomer Mark, and Dr. Richard Furman on current clinical challenges pertaining to the treatment and management of patients with multiple myeloma, chronic lymphocytic leukemia, or lymphoma. Topics discussed within this engaging session include: frontline therapies, utilization of transplant, maintenance therapy, treatment of smoldering disease, and the role of CAR T therapy for Multiple Myeloma, frontline therapies for frail and unfit patients, kinase inhibitor based therapy and management of adverse events, utilization of new therapies as monotherapies or in combination with other chemotherapies, and the role of CAR T therapy in CLL; and analysis of optimal treatment options for patients with Double Hit Lymphomas.
0 CME

Webcast: Meet the Experts: Spanish-speaking Healthcare Professionals at Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies

Meet the Experts, a panel discussion for Spanish speaking healthcare professionals, was recorded at Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies. Current clinical dilemmas in the treatment and management of multiple myeloma are discussed by the expert panel comprising of Dr. Ruben Niesvizky, Dr. Rafael Fonseca, and Dr. Koen Van Besien, with an emphasis on therapy options available to healthcare professions in South America. These engaging, audience directed conversations are presented in Spanish.
0 CME

Webcast: 2014 Advances in Inflammatory Bowel Diseases, Crohn's & Colitis Foundation's Clinical and Research Conference - Clinical and Pediatric Tracks

Dedicated to the interests of the entire community of patients with inflammatory bowel disease (IBD), and designed to meet the educational needs of all healthcare professionals who treat and manage patients with IBD, 2014 Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical and Research Conference is the foremost event for investigators and healthcare professionals to come together, share their knowledge and experience, and learn about the latest advances and new insights for personalized care of patients with IBD. This webcast was designed to meet the educational needs of all healthcare professionals who treat and manage patients with inflammatory bowel diseases, with a focus on information shared among clinicians and researchers. Participants will gain insight from expert faculty on breakthroughs in cutting-edge research and in advancements in IBD patient care.
14.5 CME

Expert Perspectives: Annual Great Debates & Updates in Melanoma 2014

In the past few years, there has been an explosion of new data on efficacious targeted and immunotherapeutic approaches for the management of malignant melanoma. Multiple treatment options currently exist with potential for clinical benefit and improvement in outcomes for melanoma patients, creating the need to fully comprehend the advantages and disadvantages of the different approaches, appropriate patient subsets that benefit from therapy, optimal combinations and sequence of therapies, and integration of evidence-based strategies into traditional modalities. As new clinical findings emerge in melanoma management, several thought-provoking issues challenge the community oncologists’ perspectives in the optimal utilization of multidisciplinary approaches to treatment of the different stages of the disease. In this video discussion, Drs. John M. Kirkwood and Antoni Ribas summarize the key take-home messages on the latest advances in melanoma research presented during the Annual Great Debates and Updates in Melanoma 2014 meeting held in Phoenix, Arizona.
0.5 CME

Expert Perspectives: 19th Annual Perspectives in Thoracic Oncology

Advances in our understanding of the molecular and genetic mechanisms underlying the pathogenesis of lung cancer have led to a dramatic expansion in the multidisciplinary approaches to the management of thoracic malignancies in the past decade with a growing number of new and improved targeted agents and efficacious combination regimens. With the advancements in the prevention, screening, and treatment of the disease, several thought-provoking issues require elucidation for thoracic oncologists to facilitate the optimal management of their patients with lung and other thoracic cancers. To further the evaluation and interpretation of emerging data, Expert Perspectives with Dr. Corey J. Langer and Dr. Anne Tsao highlights key takeaways from the 19th Annual Perspectives in Thoracic Oncology meeting.
0.25 CME

Webcast: Individualizing Therapy for Patients with Lung Cancer - What Does the Future Hold? Relating Genomics to the Potential Roles of Novel Agents

In recent years, the focus of NSCLC treatment has shifted to identifying and targeting specific tumor mutations, leading to individualized therapy. Targeting the epidermal growth factor receptor (EGFR) has played a central role in advancing NSCLC research, treatment, and patient outcomes over the last several years. Despite an initial benefit from EGFR-targeted TKIs, a majority of patients treated with these agents experience cancer recurrence due to acquired drug resistance. This unavoidable challenge has led to extensive research on resistance mechanisms and other tumor mutations that could be targeted. Currently, there are several novel agents undergoing clinical trials that target different receptor tyrosine kinases (RTKs), intracellular signaling pathways, and poly ADP ribose polymerase (PARP) proteins to improve the management of advanced NSCLC. This satellite symposium, Individualizing Therapy for Patients with Lung Cancer - What does the Future Hold?, held during the 19th Annual Perspectives in Thoracic Oncology meeting aims to provide healthcare professionals a comprehensive review of the novel targeting agents in early clinical development for lung cancer.
0.5 CME

Expert Perspectives: The Potential Impact of Molecular Profiling on Improving Clinical Outcomes for Advanced Non-small-cell Lung Carcinoma

Advances in our understanding of the molecular basis of non-small-cell lung carcinoma (NSCLC) have led to the development of effective targeted therapies, particularly tyrosine-kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR)-mutant disease. The introduction of TKIs as a treatment option, however, has led to uncertainties about their use in replacing chemotherapy and when to initiate them (first-line or second-line). Recently, the Food and Drug Administration (FDA) approved 2 real-time polymerase chain reaction (PCR) assays for the selection of TKIs (erlotinib or afatinib) as first-line treatment for advanced NSCLC patients harboring EGFR mutations. Moreover, a serum protein assay for the selection of erlotinib or chemotherapy as a second-line NSCLC treatment may likely be approved soon after promising phase III data from the PROSE trial. Expert Perspectives encompasses a video discussion that provides valuable expert opinions from Dr. Corey J. Langer and Dr. Helen Ross on the use of molecular diagnostic tests to ensure effective and personalized management of NSCLC.
0.25 CME

Best of the Day: from the 2014 Annual Hematology Meeting - CML

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Michael J. Mauro discuss clinical updates and late breaking abstracts for the therapy and management of patients with chronic myeloid leukemia (CML). This expert review discusses the importance of patient monitoring along with treatment options for frontline therapy and relapsed disease in an easily accessible format for the practicing clinician.
0.5 CME

Best of the Day: from the 2014 Annual Hematology Meeting - CLL

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Neil E. Kay discuss clinical updates and late breaking abstracts for the therapy and management of patients with chronic lymphocytic leukemia (CLL). This expert review and conversation covers prognostic factors, frontline therapy and treatment options for relapsed/refractory disease that is presented in an easily accessible format for the practicing clinician.
0.5 CME

Best of the Day: from the 2014 Annual Hematology Meeting - Multiple Myeloma

In this “Best of the Day” presentation from the 2014 Annual Hematology Meeting in San Francisco, Dr. Joseph R. Mikhael and Dr. Tomer M. Mark analyze and discuss the latest clinical data for the treatment and management of patients with multiple myeloma. This expert discussion and analysis provides updates for newly diagnosed, relapsed/refractory disease and maintenance strategies in a comprehensive, easily accessible format for the practicing clinician.